Gene: CYP2A13

1553
CPAD|CYP2A|CYPIIA13
cytochrome P450 family 2 subfamily A member 13
protein-coding
19q13.2
Ensembl:ENSG00000197838 MIM:608055 Vega:OTTHUMG00000182762 UniprotKB:Q16696
NG_007928.1
PubMed
0   ANCO-SNPs
ND
25   
NA (AD)  NA (ND)   (Frontal_Cortex)
9.251e-1 (AD)  5.905e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
LMAN1L0.471
DMBT10.445
UBTFL10.433
TP730.417
PRY20.408
DAO0.406
CYP4F120.385
KIF18B0.368
RBMXL20.362
DMRTA20.359

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
IL1RL1-0.232
C5orf34-0.217
SHISA6-0.21
VSX2-0.21
TDO2-0.207
TSHZ2-0.204
NAT16-0.199
DNAH10OS-0.199
TFRC-0.198
RFPL4B-0.194

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB00184NicotineSmall Molecule54-11-5ApprovedEnzyme
DB00553MethoxsalenSmall Molecule298-81-7ApprovedEnzyme
DB00624TestosteroneSmall Molecule58-22-0Approved|InvestigationalEnzyme
DB03783PhenacetinSmall Molecule62-44-2WithdrawnEnzyme
DB13943Testosterone cypionateSmall Molecule58-20-8ApprovedEnzyme
DB13944Testosterone enanthateSmall Molecule315-37-7ApprovedEnzyme
DB13946Testosterone undecanoateSmall Molecule5949-44-0Approved|InvestigationalEnzyme
ID Drug Name Action PubMed
C0741531,4-phenylenebis(methylene)selenocyanate"1,4-phenylenebis(methylene)selenocyanate binds to and results in decreased activity of CYP2A13 protein"21732699
C0293501-naphtholCYP2A13 protein results in increased abundance of 1-naphthol27137136
C0293501-naphthol[CYP2A13 protein results in increased oxidation of naphthalene] which results in increased abundance of 1-naphthol27137136
C0650122-ethynylnaphthalene2-ethynylnaphthalene binds to CYP2A13 protein27137136
C0650122-ethynylnaphthaleneCYP2A13 protein results in increased oxidation of 2-ethynylnaphthalene27137136
C0650122-ethynylnaphthalene[NADP co-treated with CYP2A13 protein] results in increased oxidation of 2-ethynylnaphthalene27137136
C0977453-methyleneindolenine[CYP2A13 protein results in increased metabolism of Skatole] which results in increased chemical synthesis of 3-methyleneindolenine20187624
C0067574-biphenylamineCYP2A13 protein results in increased hydroxylation of and results in increased activity of 4-biphenylamine16988941
C4822814-hydroxy-1-(3-pyridyl)-1-butanoneCYP2A13 protein results in increased abundance of 4-hydroxy-1-(3-pyridyl)-1-butanone27567546
C4822814-hydroxy-1-(3-pyridyl)-1-butanone[CYP2A13 protein results in increased metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone] which results in increased abundance of 4-hydroxy-1-(3-pyridyl)-1-butanone27567546
C4822814-hydroxy-1-(3-pyridyl)-1-butanone[CYP2A13 protein results in increased metabolism of N'-nitrosonornicotine] which results in increased abundance of 4-hydroxy-1-(3-pyridyl)-1-butanone27567546
C4822814-hydroxy-1-(3-pyridyl)-1-butanoneNicotine inhibits the reaction [[CYP2A13 protein results in increased metabolism of N'-nitrosonornicotine] which results in increased abundance of 4-hydroxy-1-(3-pyridyl)-1-butanone]27567546
C4822814-hydroxy-1-(3-pyridyl)-1-butanoneN'-nitrosoanabasine inhibits the reaction [[CYP2A13 protein results in increased metabolism of N'-nitrosonornicotine] which results in increased abundance of 4-hydroxy-1-(3-pyridyl)-1-butanone]27567546
C4822814-hydroxy-1-(3-pyridyl)-1-butanoneN'-nitrosoanatabine inhibits the reaction [[CYP2A13 protein results in increased metabolism of N'-nitrosonornicotine] which results in increased abundance of 4-hydroxy-1-(3-pyridyl)-1-butanone]27567546
C1177104-hydroxy-4-(3-pyridyl)butanoic acidCYP2A13 protein results in increased abundance of 4-hydroxy-4-(3-pyridyl)butanoic acid27567546
C1177104-hydroxy-4-(3-pyridyl)butanoic acid[CYP2A13 protein results in increased metabolism of N'-nitrosonornicotine] which results in increased abundance of 4-hydroxy-4-(3-pyridyl)butanoic acid27567546
C0165834-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanoneCYP2A13 gene polymorphism inhibits the reaction [CYP2A13 protein results in increased metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone]18669584|1866958
C0165834-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanoneCYP2A13 gene polymorphism results in decreased hydroxylation of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone17922361
C0165834-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanoneCYP2A13 protein affects the metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone12920169|1771707
C0165834-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanoneCYP2A13 protein promotes the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of H2AFX protein]26231820
C0165834-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanoneCYP2A13 protein results in increased hydroxylation of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone17922361
C0165834-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanoneCYP2A13 protein results in increased metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone17717079|1866958
C0165834-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone[CYP2A13 protein results in increased metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone] which results in increased abundance of 4-hydroxy-1-(3-pyridyl)-1-butanone27567546
C0165834-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone[CYP2A13 protein results in increased metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone] which results in increased abundance of 4-oxo-4-(3-pyridinebutanal)27567546
C0165834-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone[CYP2A13 protein results in increased metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone] which results in increased abundance of 4-oxo-4-(3-pyridyl)butanoic acid27567546
C0165834-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanoneCYP2A13 protein results in increased metabolism of and results in increased activity of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone14633739|1560812
C0165834-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanoneCYP2A13 protein results in increased metabolism of and results in increased susceptibility to 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone26231820
C0165834-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanoneCYP2A13 protein SNP results in decreased metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone14633739
C0165834-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanoneCYP2A13 results in increased activity of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone21473878
C0165834-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanoneCYP2A13 results in increased hydroxylation of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone21473878
C0165834-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanoneMethoxsalen inhibits the reaction [CYP2A13 protein results in increased metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone]18669584
C0165834-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanoneMethoxsalen inhibits the reaction [CYP2A13 protein results in increased metabolism of and results in increased activity of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone]17671098
C0165834-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanoneMetyrapone inhibits the reaction [CYP2A13 protein results in increased metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone]18669584
C0165834-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanoneMiconazole inhibits the reaction [CYP2A13 protein results in increased metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone]18669584
C0165834-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanoneTranylcypromine inhibits the reaction [CYP2A13 protein results in increased metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone]18669584
C0165834-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanoneCYP2A13 protein results in increased activity of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone22486895
C0165834-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanoneCYP2A13 protein results in increased metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone23142425
C0621454-oxo-4-(3-pyridinebutanal)CYP2A13 protein results in increased abundance of 4-oxo-4-(3-pyridinebutanal)27567546
C0621454-oxo-4-(3-pyridinebutanal)[CYP2A13 protein results in increased metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone] which results in increased abundance of 4-oxo-4-(3-pyridinebutanal)27567546
C0621454-oxo-4-(3-pyridinebutanal)[CYP2A13 protein results in increased metabolism of N'-nitrosonornicotine] which results in increased abundance of 4-oxo-4-(3-pyridinebutanal)27567546
C1177114-oxo-4-(3-pyridyl)butanoic acidCYP2A13 protein results in increased abundance of 4-oxo-4-(3-pyridyl)butanoic acid27567546
C1177114-oxo-4-(3-pyridyl)butanoic acid[CYP2A13 protein results in increased metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone] which results in increased abundance of 4-oxo-4-(3-pyridyl)butanoic acid27567546
C0913759-phenanthrolCYP2A13 protein results in increased abundance of 9-phenanthrol27137136
C0913759-phenanthrol[CYP2A13 protein results in increased oxidation of phenanthrene] which results in increased abundance of 9-phenanthrol27137136
C042552acenaphtheneCYP2A13 protein results in increased oxidation of acenaphthene25642975
C042552acenaphthene[CYP2A13 protein results in increased oxidation of acenaphthene] which results in increased chemical synthesis of acenaphthene-1-ol25642975
C023723acenaphthene-1-olCYP2A13 protein results in increased oxidation of acenaphthene-1-ol25642975
C023723acenaphthene-1-ol[CYP2A13 protein results in increased oxidation of acenaphthene] which results in increased chemical synthesis of acenaphthene-1-ol25642975
C042553acenaphthyleneCYP2A13 protein results in increased oxidation of acenaphthylene25642975
C042553acenaphthyleneCYP2A13 protein results in increased oxidation of acenaphthylene metabolite25642975
D000098AcetophenonesCYP2A13 gene polymorphism inhibits the reaction [CYP2A13 protein results in increased metabolism of Acetophenones]18669584|1866958
D000098AcetophenonesCYP2A13 protein results in increased metabolism of Acetophenones18669584
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of CYP2A13 gene27153756
D016604Aflatoxin B1[CYP2A13 protein co-treated with Aflatoxin B1] results in decreased expression of MIR1271 mRNA26084420
D016604Aflatoxin B1[CYP2A13 protein co-treated with Aflatoxin B1] results in decreased expression of MIR138-1 mRNA alternative form26084420
D016604Aflatoxin B1[CYP2A13 protein co-treated with Aflatoxin B1] results in decreased expression of MIR200B mRNA26084420
D016604Aflatoxin B1[CYP2A13 protein co-treated with Aflatoxin B1] results in decreased expression of MIR296 mRNA alternative form26084420
D016604Aflatoxin B1[CYP2A13 protein co-treated with Aflatoxin B1] results in decreased expression of MIR708 mRNA26084420
D016604Aflatoxin B1[CYP2A13 protein co-treated with Aflatoxin B1] results in increased expression of MIR181A2 mRNA26084420
D016604Aflatoxin B1[CYP2A13 protein co-treated with Aflatoxin B1] results in increased expression of MIR183 mRNA26084420
D016604Aflatoxin B1[CYP2A13 protein co-treated with Aflatoxin B1] results in increased expression of MIR335 mRNA26084420
D016604Aflatoxin B1[CYP2A13 protein co-treated with Aflatoxin B1] results in increased expression of MIR370 mRNA26084420
D016604Aflatoxin B1[CYP2A13 protein co-treated with Aflatoxin B1] results in increased expression of MIR382 mRNA26084420
D016604Aflatoxin B1[CYP2A13 protein co-treated with Aflatoxin B1] results in increased expression of MIR421 mRNA26084420
D016604Aflatoxin B1[CYP2A13 protein co-treated with Aflatoxin B1] results in increased expression of MIR425 mRNA26084420
D016604Aflatoxin B1[CYP2A13 protein co-treated with Aflatoxin B1] results in increased expression of MIR432 mRNA26084420
D016604Aflatoxin B1[CYP2A13 protein co-treated with Aflatoxin B1] results in increased expression of MIR494 mRNA26084420
D016604Aflatoxin B1[CYP2A13 protein co-treated with Aflatoxin B1] results in increased phosphorylation of AKT1 protein26084420
D016604Aflatoxin B1[CYP2A13 protein co-treated with Aflatoxin B1] results in increased phosphorylation of GSK3B protein26084420
D016604Aflatoxin B1[CYP2A13 protein co-treated with Aflatoxin B1] results in increased phosphorylation of PDPK1 protein26084420
D016604Aflatoxin B1CYP2A13 protein promotes the reaction [Aflatoxin B1 results in increased cleavage of CASP3 protein]22743290
D016604Aflatoxin B1CYP2A13 protein promotes the reaction [Aflatoxin B1 results in increased expression of PARP1 protein modified form]22743290
D016604Aflatoxin B1CYP2A13 protein results in increased metabolism of Aflatoxin B122743290|2608442
D016604Aflatoxin B1CYP2A13 protein results in increased metabolism of and results in increased activity of Aflatoxin B116917071
D016604Aflatoxin B1CYP2A13 protein results in increased susceptibility to Aflatoxin B122743290|2608442
D016604Aflatoxin B1Methoxsalen inhibits the reaction [CYP2A13 protein results in increased susceptibility to Aflatoxin B1]22743290
D016604Aflatoxin B1MIR138-1 mRNA alternative form inhibits the reaction [[CYP2A13 protein co-treated with Aflatoxin B1] results in increased phosphorylation of AKT1 protein]26084420
D016604Aflatoxin B1MIR138-1 mRNA alternative form inhibits the reaction [[CYP2A13 protein co-treated with Aflatoxin B1] results in increased phosphorylation of GSK3B protein]26084420
D016604Aflatoxin B1MIR138-1 mRNA alternative form inhibits the reaction [[CYP2A13 protein co-treated with Aflatoxin B1] results in increased phosphorylation of PDPK1 protein]26084420
D016604Aflatoxin B1Nicotine inhibits the reaction [CYP2A13 protein results in increased susceptibility to Aflatoxin B1]22743290
C072611aflatoxin B1-DNA adductCYP2A13 protein results in increased chemical synthesis of aflatoxin B1-DNA adduct22743290
C027955aflatoxin G1CYP2A13 protein affects the susceptibility to aflatoxin G123907605
C027955aflatoxin G1CYP2A13 protein results in increased activity of aflatoxin G123907605
C008615alpha-nicotyrinealpha-nicotyrine inhibits the reaction [CYP2A13 protein results in increased hydroxylation of coumarin]22486895
C008615alpha-nicotyrinealpha-nicotyrine results in decreased activity of CYP2A13 protein22486895|2522179
C547126AZM551248AZM551248 results in decreased expression of CYP2A13 mRNA22323515
D019324beta-Naphthoflavonebeta-Naphthoflavone results in increased expression of CYP2A13 mRNA22258563
C054108benzyl selenocyanatebenzyl selenocyanate binds to and results in decreased activity of CYP2A13 protein21732699
D002994ClofibrateClofibrate results in decreased expression of CYP2A13 mRNA19952500
D009249NADP[NADP co-treated with CYP2A13 protein] results in increased oxidation of 2-ethynylnaphthalene27137136
D009249NADP[NADP co-treated with CYP2A13 protein] results in increased oxidation of Phenanthrenes analog27137136
D009249NADP[NADP co-treated with CYP2A13 protein] results in increased oxidation of propargyl ether analog27137136
C030123coumarinCYP2A13 gene polymorphism results in decreased hydroxylation of coumarin17922361
C030123coumarinCYP2A13 protein results in increased hydroxylation of coumarin17922361
C030123coumarinalpha-nicotyrine inhibits the reaction [CYP2A13 protein results in increased hydroxylation of coumarin]22486895
C030123coumarinCYP2A13 protein results in increased hydroxylation of coumarin22486895
C030123coumarinmenthofuran inhibits the reaction [CYP2A13 protein results in increased hydroxylation of coumarin]22486895
C030123coumarinMenthol inhibits the reaction [CYP2A13 protein results in increased hydroxylation of coumarin]22486895
C089595cylindrospermopsincylindrospermopsin results in decreased expression of CYP2A13 mRNA23726867
D003671DEETDEET results in increased expression of CYP2A13 mRNA27091632
C036042dicyclohexyl phthalatedicyclohexyl phthalate affects the expression of CYP2A13 mRNA26924002
C010574diphenylCYP2A13 protein results in increased oxidation of diphenyl27137136
C010574diphenyldiphenyl binds to CYP2A13 protein27137136
D004726Endosulfan[Endosulfan co-treated with Tetrachlorodibenzodioxin] results in decreased expression of CYP2A13 mRNA26159488
D006492HempaCYP2A13 gene polymorphism inhibits the reaction [CYP2A13 protein results in increased metabolism of Hempa]18669584|1866958
D006492HempaCYP2A13 protein results in increased metabolism of Hempa18669584
C052901lemongrass oillemongrass oil affects the expression of CYP2A13 mRNA25976427
C052901lemongrass oillemongrass oil results in increased expression of CYP2A13 mRNA25660481
D008070LipopolysaccharidesLipopolysaccharides results in decreased expression of CYP2A13 mRNA23884085
D008070LipopolysaccharidesLipopolysaccharides results in decreased expression of CYP2A13 protein23884085
D008070Lipopolysaccharidespyrrolidine dithiocarbamic acid inhibits the reaction [Lipopolysaccharides results in decreased expression of CYP2A13 mRNA]23884085
C054487menthofuranmenthofuran inhibits the reaction [CYP2A13 protein results in increased hydroxylation of coumarin]22486895
C054487menthofuranmenthofuran results in decreased activity of CYP2A13 protein22486895
D008610MentholMenthol inhibits the reaction [CYP2A13 protein results in increased hydroxylation of coumarin]22486895
D008610MentholMenthol results in decreased activity of CYP2A13 protein22486895
D008730MethoxsalenMethoxsalen inhibits the reaction [CYP2A13 protein results in increased metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone]18669584
D008730MethoxsalenMethoxsalen inhibits the reaction [CYP2A13 protein results in increased metabolism of and results in increased activity of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone]17671098
D008730MethoxsalenMethoxsalen inhibits the reaction [CYP2A13 protein results in increased susceptibility to Aflatoxin B1]22743290
D008730Methoxsalen[Methoxsalen results in decreased activity of CYP2A13 protein] which results in decreased susceptibility to Skatole20795680
D008730MethoxsalenMethoxsalen results in decreased activity of CYP2A13 protein20795680
D012862SkatoleCYP2A13 protein results in increased metabolism of and results in increased activity of Skatole20795680
D012862SkatoleCYP2A13 protein results in increased metabolism of Skatole20187624
D012862Skatole[CYP2A13 protein results in increased metabolism of Skatole] which results in increased chemical synthesis of 3-methyleneindolenine20187624
D012862Skatole[Methoxsalen results in decreased activity of CYP2A13 protein] which results in decreased susceptibility to Skatole20795680
D008797MetyraponeMetyrapone inhibits the reaction [CYP2A13 protein results in increased metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone]18669584
D008825MiconazoleMiconazole inhibits the reaction [CYP2A13 protein results in increased metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone]18669584
C517284monomethyl phthalatemonomethyl phthalate affects the expression of CYP2A13 mRNA26924002
C031721naphthaleneCYP2A13 protein results in increased metabolism of naphthalene28599267
C031721naphthaleneCYP2A13 protein results in increased oxidation of naphthalene27137136
C031721naphthalene[CYP2A13 protein results in increased oxidation of naphthalene] which results in increased abundance of 1-naphthol27137136
C031721naphthaleneCYP2F1 protein affects the reaction [CYP2A13 protein results in increased metabolism of naphthalene]28599267
C031721naphthalene[CYP2F1 protein co-treated with CYP2A13 protein] results in increased metabolism of naphthalene28599267
C031721naphthalenenaphthalene binds to CYP2A13 protein27137136
D009538NicotineCYP2A13 protein results in increased metabolism of Nicotine22743290
D009538NicotineNicotine inhibits the reaction [[CYP2A13 protein results in increased metabolism of N'-nitrosonornicotine] which results in increased abundance of 4-hydroxy-1-(3-pyridyl)-1-butanone]27567546
D009538NicotineNicotine inhibits the reaction [CYP2A13 protein results in increased susceptibility to Aflatoxin B1]22743290
D009538NicotineNicotine results in decreased activity of CYP2A13 protein27567546
D009538NicotineCYP2A13 protein results in increased metabolism of Nicotine22486895
D009538NicotineNicotine binds to CYP2A13 protein23907605
C034629nicotine iminenicotine imine results in decreased activity of CYP2A13 protein25221795
C062567N-methyl-N-2-(methylsulfinyl)ethylpropionic acid amideCYP2A13 protein results in increased activity of N-methyl-N-2-(methylsulfinyl)ethylpropionic acid amide15725615
C014102N-methyl-N-nitrosoanilineCYP2A13 gene polymorphism inhibits the reaction [CYP2A13 protein results in increased metabolism of N-methyl-N-nitrosoaniline]18669584|1866958
C014102N-methyl-N-nitrosoanilineCYP2A13 protein results in increased metabolism of N-methyl-N-nitrosoaniline18669584
C015157N,N-dimethylaniline"CYP2A13 gene polymorphism inhibits the reaction [CYP2A13 protein results in increased metabolism of N,N-dimethylaniline]"18669584|1866958
C015157N,N-dimethylaniline"CYP2A13 protein results in increased metabolism of N,N-dimethylaniline"18669584
C010257N'-nitrosoanabasineN'-nitrosoanabasine inhibits the reaction [[CYP2A13 protein results in increased metabolism of N'-nitrosonornicotine] which results in increased abundance of 4-hydroxy-1-(3-pyridyl)-1-butanone]27567546
C010257N'-nitrosoanabasineN'-nitrosoanabasine results in decreased activity of CYP2A13 protein27567546
C032978N'-nitrosoanatabineN'-nitrosoanatabine inhibits the reaction [[CYP2A13 protein results in increased metabolism of N'-nitrosonornicotine] which results in increased abundance of 4-hydroxy-1-(3-pyridyl)-1-butanone]27567546
C032978N'-nitrosoanatabineN'-nitrosoanatabine results in decreased activity of CYP2A13 protein27567546
C036676N-nitrosoguvacolineCYP2A13 protein results in increased activity of N-nitrosoguvacoline15725615
C008655N'-nitrosonornicotineCYP2A13 protein results in increased hydroxylation of N'-nitrosonornicotine17922361
C008655N'-nitrosonornicotineCYP2A13 protein results in increased metabolism of N'-nitrosonornicotine27567546
C008655N'-nitrosonornicotine[CYP2A13 protein results in increased metabolism of N'-nitrosonornicotine] which results in increased abundance of 4-hydroxy-1-(3-pyridyl)-1-butanone27567546
C008655N'-nitrosonornicotine[CYP2A13 protein results in increased metabolism of N'-nitrosonornicotine] which results in increased abundance of 4-hydroxy-4-(3-pyridyl)butanoic acid27567546
C008655N'-nitrosonornicotine[CYP2A13 protein results in increased metabolism of N'-nitrosonornicotine] which results in increased abundance of 4-oxo-4-(3-pyridinebutanal)27567546
C008655N'-nitrosonornicotineNicotine inhibits the reaction [[CYP2A13 protein results in increased metabolism of N'-nitrosonornicotine] which results in increased abundance of 4-hydroxy-1-(3-pyridyl)-1-butanone]27567546
C008655N'-nitrosonornicotineN'-nitrosoanabasine inhibits the reaction [[CYP2A13 protein results in increased metabolism of N'-nitrosonornicotine] which results in increased abundance of 4-hydroxy-1-(3-pyridyl)-1-butanone]27567546
C008655N'-nitrosonornicotineN'-nitrosoanatabine inhibits the reaction [[CYP2A13 protein results in increased metabolism of N'-nitrosonornicotine] which results in increased abundance of 4-hydroxy-1-(3-pyridyl)-1-butanone]27567546
D016566Organoselenium CompoundsOrganoselenium Compounds binds to and results in decreased activity of CYP2A13 protein21732699
C031181phenanthreneCYP2A13 protein results in increased oxidation of phenanthrene27137136
C031181phenanthrene[CYP2A13 protein results in increased oxidation of phenanthrene] which results in increased abundance of 9-phenanthrol27137136
C031181phenanthrenephenanthrene binds to CYP2A13 protein27137136
D010616Phenanthrenes[NADP co-treated with CYP2A13 protein] results in increased oxidation of Phenanthrenes analog27137136
D010616PhenanthrenesPhenanthrenes analog binds to CYP2A13 protein27137136
D010634PhenobarbitalPhenobarbital results in decreased expression of CYP2A13 mRNA19952500
D010634PhenobarbitalPhenobarbital results in increased expression of CYP2A13 mRNA22258563
D010936Plant ExtractsPlant Extracts results in decreased expression of CYP2A13 mRNA23557933
C531209propargyl ether[NADP co-treated with CYP2A13 protein] results in increased oxidation of propargyl ether analog27137136
C531209propargyl etherpropargyl ether analog binds to CYP2A13 protein27137136
C020972pyrrolidine dithiocarbamic acidpyrrolidine dithiocarbamic acid inhibits the reaction [Lipopolysaccharides results in decreased expression of CYP2A13 mRNA]23884085
D011794QuercetinQuercetin results in decreased expression of CYP2A13 mRNA16455785
C005266quinomethionatequinomethionate affects the expression of CYP2A13 mRNA15387888
C005266quinomethionatequinomethionate results in increased expression of CYP2A13 mRNA18214805
D012293RifampinRifampin results in decreased expression of CYP2A13 mRNA22258563
D012293RifampinRifampin results in increased expression of CYP2A13 mRNA22258563
C009237senecioninesenecionine results in increased expression of CYP2A13 mRNA26100227
D013749Tetrachlorodibenzodioxin[Endosulfan co-treated with Tetrachlorodibenzodioxin] results in decreased expression of CYP2A13 mRNA26159488
D014191TranylcypromineTranylcypromine inhibits the reaction [CYP2A13 protein results in increased metabolism of 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone]18669584
D014212TretinoinTretinoin results in increased expression of CYP2A13 mRNA21376804
C574123walrycin Awalrycin A results in increased expression of CYP2A13 mRNA22314385

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004497monooxygenase activity-TAS-  
GO:0005506iron ion binding-IEA-  
GO:0008389coumarin 7-hydroxylase activity-TAS-  
GO:0008392arachidonic acid epoxygenase activity-IBA21873635  
GO:0008395steroid hydroxylase activity-IBA21873635  
GO:0016712oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen-IBA21873635  
GO:0020037heme binding-IBA21873635  
GO:0020037heme binding-IDA17428784  
GO:0070330aromatase activity-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0006082organic acid metabolic process-IBA21873635  
GO:0006805xenobiotic metabolic process-IBA21873635  
GO:0006805xenobiotic metabolic process-TAS-  
GO:0009804coumarin metabolic process-IBA21873635  
GO:0009804coumarin metabolic process-TAS-  
GO:0042738exogenous drug catabolic process-IBA21873635  
GO:0055114oxidation-reduction process-IBA21873635  
GO:0055114oxidation-reduction process-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005737cytoplasm-IBA21873635  
GO:0005789endoplasmic reticulum membrane-TAS-  
GO:0031090organelle membrane-IEA-  
GO:0043231intracellular membrane-bounded organelle-IBA21873635  
KEGG ID KEGG Term
hsa00232Caffeine metabolism
hsa00830Retinol metabolism
hsa00982Drug metabolism - cytochrome P450
hsa00983Drug metabolism - other enzymes
hsa01100Metabolic pathways
Reactome ID Reactome Term Evidence
R-HSA-1430728MetabolismTAS
R-HSA-211859Biological oxidationsTAS
R-HSA-211897Cytochrome P450 - arranged by substrate typeTAS
R-HSA-211935Fatty acidsTAS
R-HSA-211945Phase I - Functionalization of compoundsTAS
R-HSA-211981XenobioticsTAS
R-HSA-211999CYP2E1 reactionsTAS
R-HSA-5423646Aflatoxin activation and detoxificationTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
19414505CYP450 polymorphisms as risk factors for early-onset lung cancer: gender-specific differences. (2009 Jul)Timofeeva MNCarcinogenesis
21473878Metabolic effects of CYP2A6 and CYP2A13 on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced gene mutation--a mammalian cell-based mutagenesis approach. (2011 Jun 1)Chiang HCToxicol Appl Pharmacol
20846153Hypermethylation of carcinogen metabolism genes, CYP1A1, CYP2A13 and GSTM1 genes in head and neck cancer. (2010 Oct)Sharma ROral Dis
21791872Association between cancer risk and drug-metabolizing enzyme gene (CYP2A6, CYP2A13, CYP4B1, SULT1A1, GSTM1, and GSTT1) polymorphisms in cases of lung cancer in Japan. (2011)Tamaki YDrug Metab Pharmacokinet
21420395Direct genotyping of Cytochrome P450 2A6 whole gene deletion from human blood samples by the SmartAmp method. (2011 Jun 11)Azuma KClin Chim Acta
19996203Smoking-Related Gene Expression in Laser Capture-Microdissected Human Lung. (2009 Dec 15)Tan XLClin Cancer Res
25532948Genotyping of wild-type cytochrome P450 2A6 and whole-gene deletion using human blood samples and a multiplex real-time polymerase chain reaction method with dual-labeled probes. (2015 Feb 20)Shimizu MClin Chim Acta
14633739Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. (2003 Nov 15)Wang HCancer Res
16815959CYP2A13 in human respiratory tissues and lung cancers: an immunohistochemical study with a new peptide-specific antibody. (2006 Oct)Zhu LRDrug Metab Dispos
25446842Single tube genotyping of CYP2A6 gene deletion based on copy number determination by quantitative real-time PCR. (2014 Dec)Liu JHExp Mol Pathol
29027939Nicotine Component of Cigarette Smoke Extract (CSE) Decreases the Cytotoxicity of CSE in BEAS-2B Cells Stably Expressing Human Cytochrome P450 2A13. (2017 Oct 13)Ji MInt J Environ Res Public Health
28856944Inhibition of human cytochromes P450 2A6 and 2A13 by flavonoids, acetylenic thiophenes and sesquiterpene lactones from Pluchea indica and Vernonia cinerea. (2017 Dec)Boonruang SJ Enzyme Inhib Med Chem
17671098CYP2A13: variable expression and role in human lung microsomal metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. (2007 Nov)Zhang XJ Pharmacol Exp Ther
20534012Polymorphisms in CYP2A13 and UGT1A7 genes and head and neck cancer susceptibility in North Indians. (2010 Nov)Sharma ROral Dis
22706231CYP2A6: genetics, structure, regulation, and function. (2012 May 5)Raunio HDrug Metabol Drug Interact
22486895Inhibition and inactivation of cytochrome P450 2A6 and cytochrome P450 2A13 by menthofuran, beta-nicotyrine and menthol. (2012 May 30)Kramlinger VMChem Biol Interact
18669584Characterization of CYP2A13*2, a variant cytochrome P450 allele previously found to be associated with decreased incidences of lung adenocarcinoma in smokers. (2008 Nov)D'Agostino JDrug Metab Dispos
16316926CYP2A13 genetic polymorphism in French Caucasian, Gabonese and Tunisian populations. (2005 Jul)Cauffiez CXenobiotica
27725446CYP2A13 Genetic Polymorphisms in Relation to the Risk of Bladder Cancer in Japanese Smokers. (2016)Kumondai MBiol Pharm Bull
15528319Metabolism of nicotine and cotinine by human cytochrome P450 2A13. (2005 Feb)Bao ZDrug Metab Dispos
15175424Development of a real-time polymerase chain reaction-based method for the measurement of relative allelic expression and identification of CYP2A13 alleles with decreased expression in human lung. (2004 Oct)Zhang XJ Pharmacol Exp Ther
22046326'Smoking genes': a genetic association study. (2011)Verde ZPLoS One
23752126Pulmonary CYP2A13 levels are associated with early occurrence of lung cancer-Its implication in mutagenesis of non-small cell lung carcinoma. (2013 Oct)Chiang HCCancer Epidemiol
26100465Electronic cigarettes: The nicotyrine hypothesis. (2015 Sep)Abramovitz AMed Hypotheses
11684323Comparison of cytochrome P450 2A6 polymorphism frequencies in Caucasians and African-Americans using a new one-step PCR-RFLP genotyping method. (2001 Nov 30)Paschke TToxicology